scholarly journals „Rés a pajzson” – a pajzsmirigy modern képalkotó vizsgálata multidiszciplináris szemszögből

2021 ◽  
Vol 162 (14) ◽  
pp. 530-541
Author(s):  
Péter Palásti ◽  
Tamás Zombori ◽  
László Kaiser ◽  
Sándor Magony ◽  
Flóra Kakuja ◽  
...  
Keyword(s):  
Thyroid Gland ◽  
Fine Needle Biopsy ◽  
Daily Routine ◽  
Fine Needle ◽  
Routine Work ◽  
The Us ◽  
Reporting Systems ◽  
Malignant Lesions ◽  
The Relationship

Összefoglaló. A pajzsmirigy az első szervek közé tartozik, melyek megjelenítésében, betegségeinek felfedezésében az ultrahang-diagnosztikának fontos szerepe van. A pajzsmirigybetegségek a lakosság jelentős részét érintik, és a technika fejlődésével egyre több pajzsmirigyeltérés, göb kerül felfedezésre. A pajzsmirigy rosszindulatú folyamatainak nincs egy bizonyos specifikus jele, viszont az ultrahangkép alapján meghatározhatók a malignitásra gyanús eltérések. Erre az elmúlt években több összefoglaló rendszer is született. Jelen összefoglaló tanulmányunknak az a célja, hogy bemutassuk a pajzsmirigy ultrahangdiagnosztikájának fejlődését; összehasonlítsuk az egyes leletezési rendszereket, úgymint TIRADS, EU-TIRADS, K-TIRADS, melyek célja a feltehetőleg rosszindulatú göbök kiszűrése, azonosítása a mindennapi rutinmunka során; vizsgáljuk a különböző rendszerek kapcsolatát a patológia által használt Bethesda-pontrendszerrel. Az ultrahangvizsgálat megfelelő értékelése, a pontrendszerek ismerete segíthet a pajzsmirigygöb differenciáldiagnózisában, a követési frekvencia meghatározásában, csökkentheti az aspirációs citológiák számát, ezzel támogatva a klinikai döntéshozatalt. Orv Hetil. 2021; 162(14): 530–541. Summary. The thyroid gland was one of the first organs, the ultrasound (US) examination of which has played an important role. The thyroid diseases affect a large part of the population, and with the development of imaging technology, more and more thyroid abnormalities, nodules and malignant lesions are being discovered. There are no specific signs of thyroid cancer, but the suspicious signs could be determined by US. In recent years, several systems have been developed. The aim of our review is to demonstrate the development of US diagnostics of the thyroid gland; to compare the different reporting systems, such as TIRADS, EU-TIRADS, K-TIRADS, which should help to identify the questionable lesions in the daily routine work. We examine the relationship between the different US systems and the Bethesda point score used by pathologists. The literature review shows that the US examination supports the clinical decisions, helps to select, who should have a fine-needle biopsy, and allows to determine the frequency of follow-up. The number of unnecessary fine-needle biopsies could be reduced, too. Our paper is part of a bigger research, the ethical license number is 23/2020, University of Szeged. Orv Hetil. 2021; 162(14): 530–541.

scholarly journals Comparison of Ultrasound-Guided Fine-Needle Cytology Quality in Thyroid Nodules with 22-, 23-, and 25-Gauge Needles

2021 ◽  
Vol 2021 ◽  
pp. 1-7
Author(s):  
YiJie Dong ◽  
LiLi Gao ◽  
Yang Sui ◽  
MinJing Mao ◽  
WeiWei Zhan ◽  
...  
Keyword(s):  
Thyroid Nodules ◽  
Fine Needle Biopsy ◽  
Needle Aspiration ◽  
Ultrasound Guided ◽  
Fine Needle ◽  
Routine Work ◽  
First Choice ◽  
Standard Deviations ◽  
Thyroid Fna

Objective. To compare the cytology quality of ultrasound-guided fine-needle biopsy in thyroid nodules with 22-, 23-, and 25-gauge (G) needles prospectively. Methods. A total of 240 consecutive nodules underwent ultrasound-guided fine-needle aspiration (USG-FNA) and 240 nodules underwent ultrasound-guided fine-needle capillary (USG-FNC) were included in this prospective study from October 2014 to February 2016. Each nodule was sampled using 22 G, 23 G, and 25 G needle according to designed orders, and 1240 smears were finally obtained. Cytology quality was scored by a cytologist blinded to needle selection. Results. In USG-FNA, the average scores and standard deviations were 5.50 ± 2.87 for 25 G needles, 4.82 ± 2.95 for 23 G needles, and 5.19 ± 2.81 for 22 G needles. In USG-FNC, the average scores and standard deviations of each group were 5.12 ± 2.69 for 25 G, 4.60 ± 2.90 for 23 G, and 4.90 ± 2.90 for 22 G needles. The specimen quality scores of 25 G group were significantly higher than that of 23 G group ( P < 0.017 ) in both USG-FNA and USG-FNC. However, the differences were not statistically significant in nondiagnostic rate using different gauge of needles ( P > 0.017 for all). Conclusions. 25 G needles obtained the highest scores of sample quality in thyroid FNA and FNC comparing with 22 G and 23 G needles. 25 G needle should be first choice of thyroid FNA and FNC in routine work.

Balanitis Xerotica Obliterans

2007 ◽  
Vol 74 (4) ◽  
pp. 206-211
Author(s):  
C. Calcagno
Keyword(s):  
Squamous Cell Carcinoma ◽  
Clinical Presentation ◽  
Local Therapy ◽  
Line Treatment ◽  
First Line ◽  
Balanitis Xerotica Obliterans ◽  
Malignant Lesions ◽  
The Relationship ◽  
First Line Treatment

Balanitis xerotica obliterans (BXO), first described by Stuhmer in 1928, is a chronic, progressive, atrophic, sclerosing process involving prepuce, glans and urethra. Its aetiology is unknown. After a short terminological excursus and a review of the aetiological hypothesis, we have focused on BXO in daily urological practice. We are here describing the clinical presentation and its differential diagnosis with premalignant and malignant lesions of the penis. We tried to define the relationship between BXO and squamous cell carcinoma of the penis. Particular attention was then cast on urethral stenosis. Finally, we focused on the treatment of BXO: corticosteroid local therapy as first line treatment or as adjuvant therapy after circumcision, surgical therapy including circumcision, laser therapy of the glans lesions, meatoplasty in the stenosis of the anterior urethra. We also stressed the need for histological examination of the preputial specimen for a correct follow-up and for medicolegal reasons.

Use of rhDNase Therapy and Costs of Respiratory-Related Care in Patients with Cystic Fibrosis

2000 ◽  
Vol 34 (3) ◽  
pp. 304-308 ◽  
Author(s):  
Daniel A Ollendorf ◽  
Lisa J McGarry ◽  
Marc L Watrous ◽  
Gerry Oster
Keyword(s):  
Cystic Fibrosis ◽  
New England ◽  
Median Number ◽  
Deoxyribonuclease I ◽  
Outpatient Physician ◽  
Level Of Use ◽  
The Us ◽  
The Relationship ◽  
Health Hospital

OBJECTIVE: To assess the relationship between level of use of recombinant deoxyribonuclease I (rhDNase) therapy and costs of respiratory-related care in patients with cystic fibrosis. DESIGN: Retrospective, cohort study using healthcare claims data from a large New England health insurer. PATIENTS: All cystic fibrosis patients five years of age and older who began therapy with rhDNase in 1994 (the year it was first marketed in the US). Healthcare claims were compiled for six months prior to first receipt of rhDNase (pretreatment) and for 30 months subsequently (follow-up). Patients were stratified according to their level of rhDNase use during follow-up, based on whether it was above or below the median number of therapy days for the sample. MAIN OUTCOME MEASURES: Costs of rhDNase, all antibiotics, and all respiratory-related outpatient (physician, home health, hospital outpatient) and inpatient care were included. All costs were expressed on an annualized basis. RESULTS: Twenty-four patients with cystic fibrosis who began treatment with rhDNase in 1994 met all entry criteria; the median number of therapy days over a 30-month period was 355. Among patients with low (i.e., below the median) rhDNase use (n = 12), mean ± SD annualized costs of respiratory-related care increased by almost $17000 between pretreatment and follow-up, from $29251 ± $37919 to $46109 ± $40944. Among high-use patients (n = 12), costs decreased by approximately $2500, from $37178 ± $48476 to $34592 ± $22591. The change in both groups was accounted for primarily by a change in the number of respiratory-related hospitalizations. CONCLUSIONS: Prolonged use of rhDNase may reduce costs of respiratory-related care in patients with cystic fibrosis; further study is required, however, to confirm these findings.

scholarly journals A Rare Metastatic Site for Pancreatic Adenocarcinoma: A Thyroidal Metastasis

2021 ◽  
Author(s):  
Fatih Karakaya ◽  
Mehmet Bektas
Keyword(s):  
Thyroid Gland ◽  
Thyroid Nodules ◽  
Fine Needle Biopsy ◽  
Needle Aspiration ◽  
Fine Needle ◽  
Underlying Malignancy ◽  
Pet Ct ◽  
Ca 19.9 ◽  
Pet Ct Scan ◽  
Very High

Abstract BackgroundThe metastasis of pancreatic carcinoma into the thyroid gland is a rare occurrence.CaseA 43 years old female patient presented herself at the emergency department with abdominal pain and recurrent and migratory deep venous thrombosis. The abdominal computed tomography revealed intraabdominal multiple lymphadenopathy of different sizes and there was not seen ant lesion in the pancreas. CA 19.9 level was found very high (> 2016 u/ml ; reference 0–35).EUS was performed with linear echoendoscope and 30 × 28 mm solid lesion was identified in the head of pancreas. EUS-FNA was done and cytppathology resut was reported adenocarcinoma. The complaint of the patient was pain infront of the neck after the admission of the hospital.On the physical examination we detected tenderness and stiffness on the thyroid gland. The different sizes of multiple nodular formations were reported by thysoid US. A subsequent PET/CT scan was performed and it revealed hypodense pathological uptake on the thyroid gland.A ultrasound guided fine needle aspiration biopsy was performed and cytopahological result reported metastasis.ConclusionNewly developed goiter symptoms or thyroid nodules in patients with an underlying malignancy should be assessed and investigated in details. Metastasis should be ruled out by a fine needle biopsy.

scholarly journals 1179. PCV13 Pediatric Routine Schedule Completion and Adherence Before and During the COVID-19 Pandemic in the US

2021 ◽  
Vol 8 (Supplement_1) ◽  
pp. S682-S682
Author(s):  
Liping Huang ◽  
Jennifer L Nguyen ◽  
Johnna Perdrizet ◽  
Tamuno Alfred ◽  
Adriano Arguedas
Keyword(s):  
Booster Dose ◽  
Unintended Consequences ◽  
Mitigation Measures ◽  
Full Time ◽  
Primary Dose ◽  
The Us ◽  
Study Population ◽  
The Difference ◽  
The Relationship

Abstract Background Coronavirus Disease 2019 (COVID) mitigation measures may have unintended consequences, such as reduced or delayed access to routine immunizations. This study examined (1) PCV13 routine vaccination completion and adherence (C&A) among US infants before and during the COVID pandemic and (2) the relationship between primary dose C&A and booster dose C&A. Methods Retrospective data from the Optum’s de-identified Clinformatics Data Mart Database were used to create 3 cohorts: C1, Pre-COVID; C2, During COVID; C3, Cross-COVID (Figure 1). The completion was defined as number of PCV13 doses received within 8 months of birth, and the adherence was defined number of doses received at ACIP recommended time (@2, 4, 6 months, +/- 5 days). Univariable logistic regression was used to compare the odds of primary dose C&A in cohorts C1 and C3 vs C2 and descriptive analyses were used to explore primary dose C&A in relation to booster dose C&A. Figure 1: Study population and inclusion criteria Results A total of 172,916, 70,049, and 34,854 infants were included in C1, C2, and C3. Among infants with &gt; 8 months of follow-up from birth (N=132,183 for C1&C3, 16,522 for C3), 3-primary dose completion was statistically significantly higher before COVID than during COVID (crude OR = 1.10, 95% CI: 1.06-1.15). The 3-primary dose adherence was also higher before COVID than during COVID (crude OR = 1.10, 95% CI: 1.05-1.15). Among infants with ≥2, 4 and 6 months of follow-up, adherence of each individual dose was consistently higher before COVID than during COVID (1st dose: OR = 1.03, 95% CI: 1.01–1.04; 2nd dose: OR = 1.04, 95% CI: 1.01 – 1.06; 3rd dose: OR = 1.12, 95% CI: 1.08 – 1.15) (Table 1). Booster dose completion was higher in infants who completed or adhered to 3 primary doses than infants who completed or adhered to only 1 or 2 primary doses (Figure 2, Overall) and booster dose C&A was generally higher before COVID than during COVID (Figure 2, Cohort 1 vs. Cohort 3). Table 1. Comparison of completion and adherence of primary dosing series per-COVID vs. during-COVID era Figure 2: Booster dose completion and adherence in relation to primary dosing completion (A) and adherence (B) Conclusion These results indicated that PCV13 full completion was statistically lower during COVID, but the magnitude of the difference in infants was not extensive. Infants who completed or adhered to all three primary doses were more likely to complete or adhere to the booster dose. Further research is warranted as structured datasets mature to capture the full time span of COVID-19 mitigation measures. Disclosures Liping Huang, MD, MA, MS, Pfizer Inc (Employee) Jennifer L Nguyen, ScD, MPH, Pfizer Inc. (Employee) Johnna Perdrizet, MPH, Pfizer Inc (Employee) Tamuno Alfred, PhD, Pfizer Inc. (Employee) Adriano Arguedas, MD, Pfizer (Employee)

scholarly journals Thyroid Tissue Connected to Normally Located Thyroid Gland: Ectopic or Exophytic?

2012 ◽  
Vol 2012 ◽  
pp. 1-3 ◽  
Author(s):  
Erol Keles ◽  
Sule Ozkara ◽  
Turgut Karlidag ◽  
İbrahim Hanifi Ozercan
Keyword(s):  
Thyroid Gland ◽  
Needle Biopsy ◽  
Thyroid Tissue ◽  
Surgical Excision ◽  
Fine Needle Biopsy ◽  
Ectopic Thyroid ◽  
Fibrous Band ◽  
Fine Needle ◽  
Ectopic Thyroid Tissue ◽  
The Right

Ectopic thyroid tissue is seen rarely. It is often seen in cervical midline, and rarely in other areas such as submandibular area. Diagnosis is made histopathologically by fine needle biopsy after the elimination of malignancy. In the treatment of ectopic thyroid tissue, surgical excision is mostly applied. According to our knowledge, there is no exophytic thyroid tissue reported in the literature. In this paper, a 32-year-old woman who presented with a swelling under the right jaw and found a thyroid tissue attached to the normally located thyroid gland with a fibrous band in the neck was discussed.

Accuracy of fine-needle biopsy of the thyroid gland and its relationship to clinical and radiologic factors

1999 ◽  
Vol 256 (9) ◽  
pp. 476-477
Author(s):  
J. F. Carrillo ◽  
M. Frías-Mendívil ◽  
F. J. Ochoa-Carrillo ◽  
M. Ibarra ◽  
J. L. Barrera
Keyword(s):  
Thyroid Gland ◽  
Needle Biopsy ◽  
Fine Needle Biopsy ◽  
Fine Needle

The role of laboratory processing in determining diagnostic conclusiveness of breast fine needle aspirations: conventional smearing versus a monolayer preparation

2009 ◽  
Vol 62 (10) ◽  
pp. 931-934 ◽  
Author(s):  
C A P Wauters ◽  
B Kooistra ◽  
L J A Strobbe
Keyword(s):  
Ultrasound Guidance ◽  
Needle Aspiration ◽  
Processing Technique ◽  
Benign Lesions ◽  
Ultrasound Guided ◽  
Fine Needle ◽  
Malignant Lesions ◽  
The Difference

Aim:To compare breast fine needle aspiration (FNA) specimens prepared by conventional smearing (CS) versus monolayer preparation (MP), with respect to the conclusiveness of the cytopathological diagnosis.Methods:From 1992 to 1996, aspirators prepared aspirates themselves by direct smearing onto 2–4 slides. From 1999 to 2003, aspirate preparation was performed in the laboratory, creating a MP, using a Hettich cytocentrifuge. FNA diagnoses were categorised into inadequate (C1), benign (C2), atypical (C3), suspicious for malignancy (C4) and malignant (C5). The reference standard constituted histological follow-up. A conclusive FNA diagnosis was defined as C2 in lesions benign on follow-up and C5 in lesions malignant on histology.Results:From 1992 to 1996, 692 aspirates were processed by CS, whereas from 1999 to 2003, 1301 aspirates were processed by MP. More FNA were ultrasound-guided in the MP group (85.6% versus 21.5%, p<0.001). When compared with CS, MP-prepared FNA had conclusive diagnoses significantly more often (72.8% versus 58.5%, p<0.001). This effect remained significant when corrected for the difference in ultrasound guidance (adjusted odds ratio 1.7, 95% confidence interval 1.3 to 2.2, p<0.001), and was larger for malignant lesions than for benign lesions (51.7% versus 79.9%, p<0.001).Conclusion:Patients presenting with breast lesions can more often be offered a same-day, conclusive cytopathological diagnosis when FNA are prepared by a manual MP processing technique.

Fine-needle aspiration cytology of submandibular gland lesions

1995 ◽  
Vol 109 (9) ◽  
pp. 853-858 ◽  
Author(s):  
Timo Atula ◽  
Reidar Grénman ◽  
Pekka Laippala ◽  
Pekka-Juhani Klemi
Keyword(s):  
Submandibular Gland ◽  
Fine Needle Aspiration ◽  
Fine Needle Aspiration Cytology ◽  
Needle Aspiration ◽  
Aspiration Cytology ◽  
Fine Needle ◽  
Neoplastic Lesions ◽  
Malignant Lesions ◽  
Needle Aspiration Cytology

AbstractThe usefulness of fine-needle aspiration cytology (FNAC) in the diagnosis and treatment of submandibular gland lesions is not well known. The 210 FNACs taken from submandibular gland lesions at Turku University Central Hospital between 1984 and 1991 were reviewed. Of these FNACs, 78 samples from primary lesions were confirmed histologically. Within this subset 10 FNACs were taken from benign neoplasms, all of which were correctly classified (sensitivity 100 per cent; specificity 88 percent). Only four of the 14 FNACs from malignant lesions were cytologically considered malignant (sensitivity 29 per cent). On the other hand, four FNACs raised a false suspicion of malignancy (specificity 6 per cent). Out of 54 FNACs from non-neoplastic lesions 43 were correct (sensitivity 80 per cent; specificity 63 per cent). There were 104 patients (123 FNACs), who had not been operated on: the follow-up of these patients shows that in this subset of FNACs there were no false malignant but probably one false benign finding (1 per cent). We conclude that FNAC can offer valuable information about the type of the submandibular gland lesion, but the decision of operative and other treatment should not be based solely on the result of FNAC.

Sign in / Sign up

Export Citation Format

Share Document